Pfizer Metsera Bid Heats Up After Court Ruling

Pfizer Metsera bid intensifies as Pfizer matched Novo Nordisk's $10 billion offer and dropped conditions, likely extending the auction and positioning.

November 06, 2025·2 min read
View all news articles
Minimal flat-vector medical icon the Pfizer Metsera bid escalation with clean negative space.

KEY TAKEAWAYS

  • Pfizer matched Novo Nordisk's $10 billion offer and dropped bid conditions.
  • A Delaware court denied Pfizer's request, allowing Metsera to weigh the rival proposal.
  • Pfizer signaled plans to raise its offer, implying a potentially protracted auction.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Pfizer Inc. intensified its bid for Metsera, Inc. by matching a rival $10 billion offer from Novo Nordisk A/S, removing conditions from its proposal, and signaling plans to raise the offer. A Delaware Chancery Court denied Pfizer’s request to block Metsera from considering Novo Nordisk’s competing bid, allowing the board to weigh both offers.

Bidding Escalation and Court Decision

Pfizer and Novo Nordisk each submitted bids near $10 billion for Metsera, a biotech focused on obesity therapies. Pfizer notified a Delaware judge on November 5, 2025, that it had removed some conditions from its offer and was preparing to increase the bid to counter Novo Nordisk’s proposal.

On November 6, the Delaware Chancery Court denied Pfizer’s request for a temporary restraining order, permitting Metsera to consider Novo Nordisk’s offer. Metsera’s board was actively evaluating both bids. Novo Nordisk CEO Mike Doustdar expressed confidence in closing the deal, stating, “If we did not feel that we would be able to close the deal, we would not have probably entered the transaction.”

Pipeline and Market Stakes

Metsera’s pipeline includes four clinical-stage obesity programs, featuring both oral and injectable candidates. The obesity drug market is highly competitive, led by Novo Nordisk and Eli Lilly, with Pfizer seeking to expand its presence. The strategic value of Metsera’s programs has driven intense interest from established drugmakers.

No formal financial guidance, transaction terms, or integration plans have been disclosed by Metsera, Pfizer, or Novo Nordisk. The court’s decision and Pfizer’s bid adjustments suggest a potentially prolonged auction that could reshape M&A dynamics in the obesity drug sector.

HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX

Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.

Or subscribe with

Read other top news stories

Nvidia Stock Hits Record High After Intel-Led Rally

Nvidia Stock Hits Record High After Intel-Led Rally

Nvidia stock climbed to record highs after an Intel-led semiconductor rally, fueling momentum and shifting trader flows ahead of upcoming earnings.

Spotify Peloton Partnership Expands Fitness Reach

Spotify Peloton Partnership Expands Fitness Reach

Spotify Peloton partnership adds Peloton classes to Spotify's Fitness hub, widening Peloton's distribution and boosting engagement prospects for investors.

Micron Stock, SanDisk Rally After Buy Ratings

Micron Stock, SanDisk Rally After Buy Ratings

Micron stock surged after Melius Research initiated Buy coverage and set two-year targets, prompting analyst upgrades and short-term trader positioning.

Ligand Acquires XOMA Royalty

Ligand Acquires XOMA Royalty

Ligand Acquires XOMA Royalty, expanding the royalty portfolio and raising 2026 guidance to $8.50-$9.50 adjusted EPS, immediately accretive to earnings.

Domino's Q1 2026 Earnings Miss Estimates

Domino's Q1 2026 Earnings Miss Estimates

Domino's Q1 2026 earnings showed U.S. same-store sales missing forecasts and a trimmed outlook, while a $1.0B buyback reshaped investor positioning.

POET Technologies Stock Plunges After Marvell Cancels Orders

POET Technologies Stock Plunges After Marvell Cancels Orders

POET Technologies stock fell after Marvell canceled Celestial AI orders, raising revenue risk and pressuring shares ahead of the company's earnings